Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:IMNM NASDAQ:TKNO NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.94-1.1%$12.31$5.60▼$17.43$977.16M1.764.49 million shs1.69 million shsIMNMImmunome$9.21-4.9%$9.94$5.15▼$16.73$842.60M1.92772,474 shs5.21 million shsTKNOAlpha Teknova$4.45-0.4%$4.55$3.94▼$10.37$239.21M0.31143,953 shs215,431 shsTSHATaysha Gene Therapies$3.07-5.2%$2.81$1.05▼$3.40$883.86M0.983.31 million shs4.42 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.15%+4.35%+7.12%-11.13%+87.26%IMNMImmunome-4.86%-12.45%-7.99%+0.11%-36.31%TKNOAlpha Teknova-0.45%+2.06%-8.81%-18.80%-5.12%TSHATaysha Gene Therapies-5.25%-8.63%+1.32%+20.87%+32.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.94-1.1%$12.31$5.60▼$17.43$977.16M1.764.49 million shs1.69 million shsIMNMImmunome$9.21-4.9%$9.94$5.15▼$16.73$842.60M1.92772,474 shs5.21 million shsTKNOAlpha Teknova$4.45-0.4%$4.55$3.94▼$10.37$239.21M0.31143,953 shs215,431 shsTSHATaysha Gene Therapies$3.07-5.2%$2.81$1.05▼$3.40$883.86M0.983.31 million shs4.42 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.15%+4.35%+7.12%-11.13%+87.26%IMNMImmunome-4.86%-12.45%-7.99%+0.11%-36.31%TKNOAlpha Teknova-0.45%+2.06%-8.81%-18.80%-5.12%TSHATaysha Gene Therapies-5.25%-8.63%+1.32%+20.87%+32.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$18.0039.10% UpsideIMNMImmunome 3.00Buy$22.89148.52% UpsideTKNOAlpha Teknova 3.50Strong Buy$10.00124.72% UpsideTSHATaysha Gene Therapies 3.00Buy$8.29169.89% UpsideCurrent Analyst Ratings BreakdownLatest TKNO, CRMD, TSHA, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025CRMDCorMedixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$22.009/5/2025IMNMImmunomeCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/25/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/22/2025IMNMImmunomeEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$18.008/13/2025TSHATaysha Gene TherapiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.50 ➝ $8.008/12/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/8/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.008/7/2025IMNMImmunomeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$23.00 ➝ $22.008/7/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$21.007/22/2025TKNOAlpha TeknovaStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$8.007/11/2025TSHATaysha Gene TherapiesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M22.22N/AN/A$1.40 per share9.24IMNMImmunome$9.04M88.68N/AN/A$2.27 per share4.06TKNOAlpha Teknova$37.74M6.31N/AN/A$1.55 per share2.87TSHATaysha Gene Therapies$8.10M103.42N/AN/A$0.35 per share8.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.7517.2513.77N/A42.11%42.73%34.19%10/29/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.42N/AN/AN/A-55.24%-26.51%-18.40%11/6/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TKNO, CRMD, TSHA, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million8/7/2025Q2 2025TKNOAlpha Teknova-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 million8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A7.827.52IMNMImmunomeN/A12.1312.13TKNOAlpha Teknova0.175.874.70TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%IMNMImmunome44.58%TKNOAlpha Teknova13.81%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%IMNMImmunome7.69%TKNOAlpha Teknova12.50%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3074.65 million70.69 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableTKNOAlpha Teknova24053.51 million46.83 millionNot OptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTKNO, CRMD, TSHA, and IMNM HeadlinesRecent News About These CompaniesTaysha Gene Therapies, Inc. $TSHA Shares Acquired by Octagon Capital Advisors LPSeptember 11 at 6:03 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 52-Week High - Here's WhySeptember 7, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus PT from AnalystsSeptember 5, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. $TSHA Stake Increased by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comNuveen LLC Acquires New Stake in Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comTaysha Gene Therapies, Inc.September 3, 2025 | edition.cnn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 3, 2025 | marketbeat.comPiper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9August 25, 2025 | msn.comKovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHAAugust 24, 2025 | marketbeat.comFY2025 Earnings Forecast for TSHA Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for TSHA EarningsAugust 17, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeAugust 15, 2025 | marketbeat.comWells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00August 15, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00August 14, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13, 2025 | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsAugust 13, 2025 | marketbeat.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13, 2025 | finance.yahoo.comXTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)August 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTKNO, CRMD, TSHA, and IMNM Company DescriptionsCorMedix NASDAQ:CRMD$12.94 -0.15 (-1.15%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.03 +0.09 (+0.70%) As of 09/12/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Immunome NASDAQ:IMNM$9.21 -0.47 (-4.86%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.32 +0.11 (+1.19%) As of 09/12/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Alpha Teknova NASDAQ:TKNO$4.45 -0.02 (-0.45%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.45 0.00 (0.00%) As of 09/12/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.Taysha Gene Therapies NASDAQ:TSHA$3.07 -0.17 (-5.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.10 +0.03 (+0.98%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
